Guardant360 TissueNextTM is a next-generation sequencing (NGS)-based pan-cancer tissue test for patients with advanced solid tumor. The test allows oncologists to identify actionable biomarkers for therapeutic management.
The Guardant360 TissueNextTM test report covers 84 genes and will include Tumor Mutational Burden (TMB), Microsatellite Instability (MSI) status, Homologous Recombination Repair (HRR) genes and selected fusions.
Guardant360 TissueNext covers alterations in 84 genes relevant to multiple solid tumors, also TMB and MSI status.
Guardant Health precision oncology products – Guardant
RevealTM, Guardant360® CDx, Guardant360 TissueNextTM
are available in Hong Kong through the designated local partner, Codex
Genetics.
The retrieved liquid or tumor biopsy will be performed at Guardant
Health laboratory in California, the United States.
Patients are encouraged to discuss genetic testing options with their
healthcare provider. For questions about how to access the tests, please
feel free to
contact us.
Sample shipment will be arranged on the same or the next day upon sample
retrieval. Upon sample received in Guardant Health laboratory in the US,
the test report will be ready in around 21 days.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.
Codex Genetics enables precision medicine through AI-powered analytics on both genetic and clinical data. We aim to provide holistic, clinically actionable disease management solutions for medical professionals and individuals. We provide services to accelerate diagnostic processes and help disease treatment and disease management.
